Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial
The Oncologist · 04.03.2024 · 29 (3) · e319-e329
DOI: 10.1093/oncolo/oyad301 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 16.11.2023. Verfasst von Eriko Tokunaga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Aminopyridines, Benzimidazoles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Background
Established prognostic factors for treatment response to cyclin-dependent kinases 4 and 6 inhibitors are currently lacking. We aimed to investigate the relationship of pretreatment neutrophil-to-lymphocyte ratio (NLR) and absolute lymphocyte count (ALC) to abemaciclib outcomes. Patients and Methods This was a post hoc analysis of data from MONARCH 2, a phase III study of abemaciclib or placebo plus fulvestrant in hormone-receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer that progressed on endocrine therapy. Patients were divided into high and low categories based on baseline NLR (cutoff: 2.5) and ALC (cutoff: 1.5 × 109/L). The association of baseline NLR and ALC with progression-free survival (PFS) and overall survival (OS) was explored using Cox models and Kaplan-Meier estimates. Tumor response and safety were also examined.
Results
NLR and ALC data were available for 645 patients (abemaciclib: N = 426; placebo: N = 219). Low-baseline NLR or high-baseline ALC was consistently associated with positive PFS and OS trends; low-baseline NLR subgroups also showed trends for better response. The abemaciclib treatment effect against placebo was observed regardless of baseline NLR or ALC. Univariate analyses showed baseline NLR and ALC were prognostic of PFS and OS. Baseline NLR remained significant in the multivariate model (P < .0001). No unexpected differences in safety were observed by baseline NLR or ALC.
Conclusion
Baseline NLR was independently prognostic of PFS and OS. Low-baseline NLR was associated with numerically better efficacy outcomes, but the benefit of adding abemaciclib to fulvestrant was similar irrespective of baseline NLR status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
- Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Hyogo, Japan.
- Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan.
- Director, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
ORCID-Profile: Masakazu Toi
Förderung
- Eli Lilly and Company
Zitieren
APA
Tokunaga, E., Miyoshi, Y., Dozono, K., Kawaguchi, T., & Toi, M. (2024). Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial. The Oncologist, 29(3), e319-e329. https://doi.org/10.1093/oncolo/oyad301
Vancouver
Tokunaga E, Miyoshi Y, Dozono K, Kawaguchi T, Toi M. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial. The Oncologist. 2024;29(3):e319-e329. doi:10.1093/oncolo/oyad301
BibTeX
@article{Tokunaga2024,
author = {Tokunaga, Eriko and Miyoshi, Yasuo and Dozono, Koji and Kawaguchi, Tsutomu and Toi, Masakazu},
title = {Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {3},
pages = {e319--e329},
doi = {10.1093/oncolo/oyad301}
}
EUVIMED